Yellow Fever- Pipeline Insight, 2025

This “Yellow Fever- Pipeline Insight, 2025” report provides comprehensive insights about 3+ companies and 3+ pipeline drugs in Yellow Fever pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Yellow Fever: Understanding

Yellow Fever: Overview

Yellow fever is a viral hemorrhagic disease caused by the yellow fever virus (YFV), a member of the Flavivirus genus, which is primarily transmitted by the Aedes aegypti mosquito. Endemic to tropical regions of Africa and South America, yellow fever presents a significant public health challenge due to its potential for rapid outbreaks. The virus typically infects humans, monkeys, and mosquitoes, contributing to an intricate transmission cycle in both urban and jungle environments. Once a person is bitten by an infected mosquito, the virus enters the bloodstream and primarily targets the liver, causing a spectrum of symptoms. These can range from mild fever, muscle pain, and headache in mild cases, to more severe manifestations such as jaundice, internal bleeding, and multi-organ failure in advanced stages. The name 'yellow' fever comes from the jaundice that characterizes severe cases of the disease.

The progression of yellow fever can be divided into three stages: an initial stage with flu-like symptoms, a brief remission period, and a toxic phase where liver and kidney dysfunction become prominent. The mortality rate during the toxic phase is high, with 20-50% of untreated cases resulting in death. Survivors generally gain lifelong immunity. Despite the serious nature of the disease, yellow fever is preventable through vaccination. The 17D yellow fever vaccine, developed in the 1930s, provides lifelong protection after a single dose and is highly effective. However, access to the vaccine remains a challenge in many high-risk areas, especially in regions with limited healthcare infrastructure. Periodic outbreaks still occur, often exacerbated by factors like urbanization, deforestation, and climate change, which increase human exposure to infected mosquito populations.

Efforts to control yellow fever also include vector control programs aimed at reducing mosquito populations through insecticide use and eliminating breeding sites. However, vector control has had limited long-term success due to the adaptability of mosquitoes and the complexity of implementing sustainable measures. The World Health Organization (WHO) has launched initiatives like the Eliminate Yellow Fever Epidemics (EYE) strategy to address vaccine shortages, improve surveillance, and strengthen preventive campaigns in endemic regions. Despite these efforts, yellow fever continues to pose a significant risk to global health, with the potential for international spread due to global travel and trade.

'Yellow Fever- Pipeline Insight, 2025' report outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Yellow Fever pipeline landscape is provided which includes the disease overview and Yellow Fever treatment guidelines. The assessment part of the report embraces, in depth Yellow Fever commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Yellow Fever collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Yellow Fever R&D. The therapies under development are focused on novel approaches to treat/improve Yellow Fever.

Yellow Fever Emerging Drugs Chapters

This segment of the Yellow Fever report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Yellow Fever Emerging Drugs

SP0218 : Sanofi

SP0218 is a subcutaneous formulation of a yellow fever vaccine being developed by Sanofi for the prevention of yellow fever. The drug is currently in Phase II stage of clinical trials for the evaluation of Yellow fever.

HydroVax-002 YFV : Najít Technologies

HydroVax-002 YFV is a novel inactivated vaccine which acts by stimulating the immune response. The vaccine candidate is based on HydroVax technology. It is administered through intramuscular route. The drug is currently in Phase I stage of clinical trials for the evaluation of Yellow fever.

Yellow Fever: Therapeutic Assessment

This segment of the report provides insights about the different Yellow Fever drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Yellow Fever

• There are approx. 3+ key companies which are developing the therapies for Yellow Fever. The companies which have their Yellow Fever drug candidates in the most advanced stage, i.e. phase II include, Sanofi

Phases

The report covers around 3+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Route of Administration

Yellow Fever pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Oral
• Intravenous
• Subcutaneous
• Parenteral
• Topical

Molecule Type

Products have been categorized under various Molecule types such as

• Recombinant fusion proteins
• Small molecule
• Monoclonal antibody
• Peptide
• Polymer
• Gene therapy

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Yellow Fever: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Yellow Fever therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Yellow Fever drugs.

Yellow Fever Report Insights

• Yellow Fever Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Yellow Fever Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Yellow Fever drugs?
• How many Yellow Fever drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Yellow Fever?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Yellow Fever therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Yellow Fever and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Sanofi
• Najit Technologies, Inc.

Emergex Vaccines

Key Products

• SP0218
• HydroVax-002 YFV
• Research programme: yellow fever booster vaccine

This product will be delivered within 2 business days.